Summit Therapeutics Inc.

Verified identity

Start with the filing record

The identity and ticker come from the SEC’s official company ticker mapping. Market and editorial coverage are not inferred from that record.

Ticker: SMMT
CIK: 0001599298
Exchange: Nasdaq
Universe updated: 2026-08-22

Open SEC filings

Market price

Latest quoteOpens Google

TickerGrove coverage

Latest on Summit Therapeutics Inc.

Companies

Akeso reported a China overall survival benefit for ivonescimab. It is not a U.S. approval.

Akeso's China HARMONi-2 Phase III showed a statistically significant OS gain for ivonescimab vs pembrolizumab in PD-L1-positive advanced NSCLC. OS HR not printed. Investigational in Summit territories. HARMONi PDUFA November 14, 2026.

Published 09-03-2026 · Summit Therapeutics Inc.

Research foundation

Read the filing with the right frame

Company analysis

Revenue, EPS and guidance answer different earnings questions

Revenue is the top-line amount recognized from a company’s activities under its accounting policy.

Earnings reading room →

Company analysis

The three financial statements describe one business from different angles

The income statement records revenue and expenses over a period.

Company research desk →

Investing basics

Stocks, ETFs and indexes are different objects

A stock is an ownership interest in one company.

Company research desk →